Shares of Oracle (ORCL) rose about 4% on Wednesday after Oppenheimer upgraded the stock to Outperform from Perform.
Objective To assess whether post-authorisation studies registered with the European Medicines Agency (EMA) adhere to legislation and recommendations to publicly post study protocols and results.